Roche will present significant ophthalmology data at the ARVO Annual Meeting, highlighting their commitment to vision preservation. Real-world evidence from the VOYAGER study will showcase Vabysmo's efficacy in drying retinas for nAMD and DME patients. These findings demonstrate consistent improvements in both treatment-naïve and previously treated individuals. The company will also present new data for Susvimo, emphasizing its potential for long-lasting disease control with reduced treatment burden. Additionally, early insights into the investigational IL-6 inhibitor, vamikibart, will be shared. These presentations cover a range of retinal conditions including geographic atrophy and uveitic macular edema. Roche is showcasing over 45 abstracts, with 20 oral presentations, underlining their broad ophthalmology pipeline. Vabysmo, a bispecific antibody, targets Ang-2 and VEGF-A pathways to stabilize blood vessels. Susvimo utilizes a refillable implant for continuous ranibizumab delivery. Vamikibart is an investigational antibody targeting IL-6 for inflammatory retinal conditions.